Advancements in dermatological treatments and diagnostic technology highlight recent developments in healthcare and medical research.
Key Points
New data confirms the long-term effectiveness of the oral IL-23 inhibitor icotrokinra for treating moderate to severe psoriasis through two years of use.
A phase 3 head-to-head trial revealed that zasocitinib is 2.5 times more effective than deucravacitinib in achieving completely clear skin for plaque psoriasis patients.
Recent clinical trials have identified three new targeted treatment options for hidradenitis suppurativa that successfully interrupt the disease's underlying pathophysiology.
A retrospective study demonstrates that avelumab provides effective treatment for Merkel cell carcinoma in diverse real-world patient populations often excluded from traditional clinical trials.
Clinical trials involving CAR T-cell therapy for autoimmune diseases remain suspended following three patient deaths, prompting an investigation into the safety and future of these treatments.
A novel smartphone-based 3D imaging tool shows clinical accuracy comparable to specialists in assessing eyelid ptosis, potentially streamlining surgical decision-making.
Analysis of UK Biobank data suggests that retinal neurodegenerative changes can occur at hemoglobin A1c levels currently considered below the threshold for prediabetes.
Healthcare cybersecurity experts are raising alarms regarding the vulnerability of medical infrastructure following a recent AI-driven cyberattack on an Australian government health website.